Recent developments include strategic collaborations, capital raises, clinical trial progress, and financial results reflecting ongoing transformation and operational challenges.

• Exicure announced a co-development agreement with Adbiotech for Burixafor targeting multiple indications [N1].
• The company secured $8.7 million in a stock purchase deal with significant stockholder HiTron [N2].
• Shares surged 41% following promising Phase 2 clinical data for a Multiple Myeloma drug [N3].
• Exicure's stock soared on Burixafor data from a Multiple Myeloma trial, reflecting positive clinical progress [N4].
• The company topped after-hours gainers with a 72% jump following Burixafor data release [N5].
• Reported a net loss of $2.44 million in Q3 2025, indicating ongoing operating challenges [N6].
• Stock price movements occurred after clinical updates and strategic moves alongside other biotech stocks [N7].
• Exicure posted wider losses in fiscal Q2 2025, reflecting continued financial pressures [N8].

Exicure's acquisition of GPCR USA and collaboration on CXCR4 inhibitor development, including completion of a Phase 2 clinical trial, represent potential value drivers. The company's focus on strategic alternatives and partnerships, especially in Asia, may open new growth avenues. Recent positive clinical data and capital raises demonstrate investor interest and potential for business transformation.

Exicure faces significant risks including lack of current revenue, limited liquidity, and dependence on securing additional financing. The company has no proprietary intellectual property following asset sales and limited operational capabilities. Governance challenges due to inexperienced management and board, as well as ongoing legal matters, add to execution risks. Failure to complete strategic transactions or obtain funding could adversely impact operations and stockholder value.

Exicure's historical biotechnology intellectual property and proprietary SNA technology platform were sold in 2024, and the company no longer owns these assets. Its current business model centers on strategic transactions and collaborations, such as the acquisition of GPCR USA and licensing agreements, rather than proprietary technology development. The company's moat is limited given the absence of owned intellectual property and reliance on partnerships and strategic alternatives for growth.

• Liquidity and Financing Risk: Exicure has limited cash and no current revenue, requiring substantial additional financing to continue operations and pursue strategic alternatives. Failure to secure funding on acceptable terms could impair business continuity.
• Execution Risk of Strategic Alternatives: The company's plan to grow through acquisitions and partnerships involves complex, time-consuming transactions with no assurance of success or favorable terms. Management's limited experience in U.S. public markets may hinder execution.
• Governance and Management Risk: Recent turnover and limited experience of board members and executives in public company governance may affect compliance, risk management, and strategic decision-making.
• Regulatory and Legal Risks: Exicure is subject to ongoing litigation including securities class actions and derivative lawsuits. Regulatory compliance and potential legal liabilities could impact financial condition and reputation.
• Market and Stockholder Concentration Risk: Significant stockholders such as HiTron hold substantial influence, which may deter other investors and affect corporate governance and strategic decisions.

• Exicure, Inc. historically was an early-stage biotechnology company focused on nucleic acid therapies targeting RNA but ceased research and development activities in September 2022 and sold its historical biotechnology intellectual property and assets in 2024 [S1].
• The company no longer owns intellectual property related to its prior therapeutic candidates or SNA technology platform after the 2024 asset sale [S1].
• Exicure is currently exploring strategic alternatives including acquisitions, partnerships, and capital raises, with a focus on growth through transactions with potential partners, especially in Asia [S1].
• In January 2025, Exicure acquired GPCR Therapeutics USA Inc., a subsidiary of GPCR Therapeutics Inc., and entered into a License and Collaboration Agreement to develop and commercialize GPCR's technologies, including a CXCR4 inhibitor [S1].
• GPCR USA completed a Phase 2 clinical trial in January 2026 involving a combination of GPC-100 and propranolol for stem cell mobilization in Multiple Myeloma patients [S1].
• Exicure intends to make a $1 million milestone payment to GPCR in Q2 2026 in shares of common stock as part of the License and Collaboration Agreement [S1].
• The company formed a wholly-owned South Korean subsidiary, KC Creation Co., Ltd., in March 2025 for potential growth strategies but decided to sell it in November 2025 [S1].
• Significant stockholder HiTron owns approximately 25% of Exicure's outstanding common stock as of March 2026, having purchased shares in late 2024 and early 2025 [S1].
• Exicure has no current source of revenue and has incurred significant operating losses historically, including a net loss of $1.8 million in Q1 2026 and an accumulated deficit of $223 million as of December 31, 2025 [S1, S2].
• The company reported cash and cash equivalents of approximately $4.4 million as of September 30, 2025, with a current ratio of 0.79 and a cash ratio of 1.0 as of March 31, 2026 [S2].
• Exicure has limited liquidity and requires substantial additional financing to continue operations and pursue strategic alternatives [S1].
• The company has no manufacturing or sales and marketing capabilities following the wind down of its research and development programs [S1].
• Recent news highlights include co-development of Burixafor with Adbiotech for multiple indications, promising Phase 2 data for a Multiple Myeloma drug, and a $8.7 million stock purchase deal with HiTron [N1][N2][N3][N4][N5].
• Exicure's shares experienced significant price movements following clinical trial data releases and strategic announcements, including a 41% surge on promising Phase 2 data and a 72% jump after-hours on Burixafor data [N3][N5].
• The company reported losses of $2.44 million in Q3 2025 and wider losses in fiscal Q2 2025 [N6][N8].
• Exicure's board and management have limited experience with U.S. public company governance, and recent turnover in board members and senior management has occurred [S1].
• The company faces risks related to its ability to obtain additional funding, execute strategic transactions, and maintain Nasdaq listing compliance [S1].
• Exicure is involved in ongoing legal matters including a securities class action settlement and other litigation, with some settlements covered by insurance [S1].